Overview

An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus

Status:
Not yet recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

This is a monocenter, open-label Phase II trial for refractory SLE patients currently on stable background immunosuppressive therapy. Treatment in this trial will be daratumumab weekly for a period of 8 weeks. This study will enroll 10 patients.

Phase:

Phase 2

Details

Lead Sponsor:

Charite University, Berlin, Germany

Collaborators:

Charité Clinical Trial Office (CTO)
Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)
Janssen-Cilag G.m.b.H
Labor Berlin-Charité Vivantes G.m.b.H

Treatments:

Daratumumab